First Time Loading...
A

Aurisco Pharmaceutical Co Ltd
SSE:605116

Watchlist Manager
Aurisco Pharmaceutical Co Ltd
SSE:605116
Watchlist
Price: 23.35 CNY -1.44% Market Closed
Updated: May 17, 2024
Aurisco Pharmaceutical Co Ltd
/
Income Statement
/
Income from Continuing Operations

Aurisco Pharmaceutical Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aurisco Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison

Comparables:
H
3692
600436
600276
000538
S
688506

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
A
Aurisco Pharmaceutical Co Ltd
SSE:605116
Income from Continuing Operations
¥208.2m
CAGR 3-Years
4%
CAGR 5-Years
36%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Income from Continuing Operations
¥3.3B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Income from Continuing Operations
¥3.1B
CAGR 3-Years
19%
CAGR 5-Years
20%
CAGR 10-Years
21%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Income from Continuing Operations
¥4.4B
CAGR 3-Years
-12%
CAGR 5-Years
1%
CAGR 10-Years
13%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Income from Continuing Operations
¥4.3B
CAGR 3-Years
-5%
CAGR 5-Years
-1%
CAGR 10-Years
6%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Income from Continuing Operations
-¥780.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Aurisco Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
208.2m CNY

Based on the financial report for Dec 31, 2022, Aurisco Pharmaceutical Co Ltd's Income from Continuing Operations amounts to 208.2m CNY.

What is Aurisco Pharmaceutical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
36%

Over the last year, the Income from Continuing Operations growth was 24%. The average annual Income from Continuing Operations growth rates for Aurisco Pharmaceutical Co Ltd have been 4% over the past three years , 36% over the past five years .

ALPHA SPREAD
Join more than 138,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.